GlassScriptPhysician profile
Fernanda N Dasilva
NPI 1578593778
$10,222.17
in general payments reported to CMS, 2019-2025
47 companies · $1,952 in 2025
The $1,952 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,521 · 2020: $981 · 2021: $1,254 · 2022: $1,120 · 2023: $1,718 · 2024: $1,677 · 2025: $1,952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,337 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,337.42 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,078.99 | 2019-2024 | Spravato, Xarelto |
| Lilly USA, LLC | $1,056.93 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Novo Nordisk INC | $1,042.74 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $760.24 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $700.07 | 2021-2025 | |
| Abbvie INC. | $607.53 | 2019-2025 | Qulipta, Vraylar, Linzess |
| Pfizer INC. | $588.79 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $507.60 | 2019-2025 | Jardiance |
| Amgen INC. | $461.91 | 2019-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $387.86 | 2019-2025 | Gardasil 9, Vaxneuvance, Rotateq |
| Glaxosmithkline, LLC. | $378.67 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbott Laboratories | $274.50 | 2019-2025 | Freestyle Libre 3, Eterna, Freestyle Libre 2 |
| Amarin Pharma, INC. | $226.81 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $221.69 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $211.66 | 2019-2024 | Xifaxan |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernanda Dasilva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.